Literature DB >> 11445189

Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes.

H J Herdon1, F M Godfrey, A M Brown, S Coulton, J R Evans, W J Cairns.   

Abstract

Two distinct types of glycine transporter, GlyT-1 and GlyT-2, have been characterised. GlyT-1 and GlyT-2 are known to be differentially expressed amongst CNS areas, but direct functional evidence for their relative contributions to high-affinity glycine uptake by brain tissues is lacking. In the present study, we have used the selective GlyT-1 inhibitor N[3-(4"-fluorophenyl)-3-(4"-phenylphenoxy)propyl]sarcosine (NFPS) to investigate the role of GlyT-1 in mediating glycine uptake. HEK293 cells expressing human GlyT-1c or GlyT-2 showed high levels of Na(+)-dependent glycine uptake, with K(m) values of 117+/-13 and 200+/-22 microM, respectively. NFPS potently inhibited uptake in GlyT-1c cells (IC(50) value 0.22+/-0.03 microM), being around 500-fold more potent than glycine or sarcosine, but had no effect on uptake in GlyT-2 cells (IC(50) >10 microM). Efflux of pre-loaded [3H]-glycine from GlyT-1c cells was increased by glycine or sarcosine, whereas NFPS had no effect on its own but blocked the effects of glycine or sarcosine. These results confirm that NFPS is a potent, selective and non-transportable GlyT-1 inhibitor. Rat cortex and cerebellum synaptosomes also showed a high-affinity Na(+)-dependent component of glycine uptake, with affinities similar to those observed for uptake in GlyT-1c or GlyT-2 cells. In cortex synaptosomes, NFPS and sarcosine produced the same maximal inhibition of uptake as glycine itself. However, in cerebellum synaptosomes, the maximal inhibition produced by NFPS and sarcosine was only half that produced by glycine. In both tissues NFPS was around 1000-fold more potent than glycine or sarcosine. Overall, our findings indicate that high-affinity glycine uptake in cerebral cortex occurs predominantly via GlyT-1. However, in cerebellum, only a part of the high-affinity uptake is mediated by GlyT-1, with the remaining NFPS-insensitive component most likely mediated by GlyT-2.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445189     DOI: 10.1016/s0028-3908(01)00043-0

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  13 in total

1.  Alterations in brain extracellular dopamine and glycine levels following combined administration of the glycine transporter type-1 inhibitor Org-24461 and risperidone.

Authors:  Katalin Nagy; Bernadett Marko; Gabriella Zsilla; Peter Matyus; Katalin Pallagi; Geza Szabo; Zsolt Juranyi; Jozsef Barkoczy; Gyorgy Levay; Laszlo G Harsing
Journal:  Neurochem Res       Date:  2010-08-20       Impact factor: 3.996

Review 2.  Glycine receptors and glycine transporters: targets for novel analgesics?

Authors:  Hanns Ulrich Zeilhofer; Mario A Acuña; Jacinthe Gingras; Gonzalo E Yévenes
Journal:  Cell Mol Life Sci       Date:  2017-08-08       Impact factor: 9.261

Review 3.  Cognitive enhancers for facilitating drug cue extinction: insights from animal models.

Authors:  Bríd Áine Nic Dhonnchadha; Kathleen M Kantak
Journal:  Pharmacol Biochem Behav       Date:  2011-02-02       Impact factor: 3.533

4.  The glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonist.

Authors:  Hai Xia Zhang; Ariel Lyons-Warren; Liu Lin Thio
Journal:  Neuropharmacology       Date:  2009-07-18       Impact factor: 5.250

Review 5.  The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia.

Authors:  Joseph T Coyle; Guochuan Tsai
Journal:  Psychopharmacology (Berl)       Date:  2003-11-25       Impact factor: 4.530

6.  Some Operational Characteristics of Glycine Release in Rat Retina: The Role of Reverse Mode Operation of Glycine Transporter Type-1 (GlyT-1) in Ischemic Conditions.

Authors:  Adrienn Hanuska; Gábor Szénási; Mihaly Albert; Laszlo Koles; Agoston Varga; Andras Szabo; Peter Matyus; Laszlo G Harsing
Journal:  Neurochem Res       Date:  2015-09-12       Impact factor: 3.996

7.  The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine.

Authors:  Hai Xia Zhang; Krzysztof Hyrc; Liu Lin Thio
Journal:  J Physiol       Date:  2009-05-11       Impact factor: 5.182

Review 8.  Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.

Authors:  Robert W Buchanan; Robert Freedman; Daniel C Javitt; Anissa Abi-Dargham; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2007-07-19       Impact factor: 9.306

9.  Chemically induced acute model of sarcosinemia in wistar rats.

Authors:  Rodrigo Binkowski de Andrade; Tanise Gemelli; Denise Bertin Rojas; Carlos Severo Dutra-Filho; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2015-11-12       Impact factor: 3.584

10.  SLC6A20 transporter: a novel regulator of brain glycine homeostasis and NMDAR function.

Authors:  Mihyun Bae; Junyeop Daniel Roh; Youjoung Kim; Seong Soon Kim; Hye Min Han; Esther Yang; Hyojin Kang; Suho Lee; Jin Yong Kim; Ryeonghwa Kang; Hwajin Jung; Taesun Yoo; Hyosang Kim; Doyoun Kim; Heejeong Oh; Sungwook Han; Dayeon Kim; Jinju Han; Yong Chul Bae; Hyun Kim; Sunjoo Ahn; Andrew M Chan; Daeyoup Lee; Jin Woo Kim; Eunjoon Kim
Journal:  EMBO Mol Med       Date:  2021-01-11       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.